25 studies found for:    "methodist hospital" | Open Studies | "Breast Neoplasms" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: TDM1;   Drug: Lapatinib;   Drug: Abraxane
2 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
3 Recruiting Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Hydroxytyrosol
4 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel
5 Recruiting PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anthracycline based chemotherapy;   Drug: taxane-based chemotherapy
6 Recruiting Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)
Conditions: Breast Neoplasms;   Breast Cancer
Interventions: Drug: Taxane;   Drug: Taxotere;   Drug: Abraxane;   Drug: Ixabepilone
7 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
8 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
9 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
10 Recruiting Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Condition: Ductal Breast Carcinoma in Situ
Interventions: Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
11 Not yet recruiting TAA-SPECIFIC CTLS FOR SOLID TUMORS (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Glioma/Medulloblastoma;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
12 Recruiting Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation
13 Recruiting S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer
Interventions: Dietary Supplement: cholecalciferol;   Other: placebo
14 Recruiting Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Reparixin
15 Recruiting The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Radiolabeled (99mTc) GP (Glycopeptide)
16 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docetaxel;   Drug: carboplatin;   Biological: trastuzumab;   Biological: pertuzumab;   Drug: goserelin acetate;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis;   Drug: aromatase inhibition therapy;   Other: quality-of-life assessment
17 Recruiting A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Condition: HER2+ Metastatic Breast Cancer (MBC)
Interventions: Drug: neratinib;   Drug: capecitabine;   Drug: lapatinib
18 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
19 Recruiting A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant;   Drug: BKM120;   Drug: BKM120 matching placebo
20 Recruiting Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole;   Drug: BYL719

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years